Brief: Spero Therapeutics provides Tebipenem HBR Program Update following Type A meeting with the U.S. FDA
06/09/2022 13:11
Sept 6 (Reuters) - Spero Therapeutics Inc SPRO.O :
* SPERO THERAPEUTICS PROVIDES TEBIPENEM HBR PROGRAM UPDATE
FOLLOWING TYPE A MEETING WITH THE U.S. FOOD AND DRUG
ADMINISTRATION
* PLANS TO ADVANCE TEBIPENEM HBR'S CLINICAL DEVELOPMENT AND
POTENTIAL COMMERCIALIZATION THROUGH EXTERNAL PARTNERSHIP
* FDA FEEDBACK INDICATES POSITIVE RESULTS FROM A SINGLE
ADDITIONAL
PHASE 3 CLINICAL TRIAL IN PATIENTS WITH COMPLICATED UTI
Source text for Eikon: ID:nGNX73H0PZ
Further company coverage: SPRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)